Interestingly, the efficacy of BTK inhibitors in PCNSL is distinct from their performance in systemic lymphoma, where the single agent ibrutinib achieves only a 10% CR rate and a 15% PR rate (2). The gene discussed is BTK; the disease is lymphoma.